Showing results (91-100 of 522) with videos related to

Sort By:
Pageof 53
European Journal of Cancer (Oxford, England : 1990)|April 10, 2019
Switch to anti-programmed cell death protein 1 (anti-PD-1) fixed-dose regimen: What is the economic impact?Arnaud Bayle, Benjamin Besse, Maxime Annereau, et al.
Clinical Lung Cancer|June 6, 2022
Clinical Utility and Outcomes Impact of Crystal Digital PCR of Sensitizing and Resistance EGFR Mutations in Patients With Advanced Non-Small Cell Lung CancerMariona Riudavets, Virginie Lamberts, Damien Vasseur, et al.
Plos One|June 12, 2020
Outcomes in oncogenic-addicted advanced NSCLC patients with actionable mutations identified by liquid biopsy genomic profiling using a tagged amplicon-based NGS assayJordi Remon, Aurelie Swalduz, David Planchard, et al.
Lung Cancer (Amsterdam, Netherlands)|December 2, 2017
Prognostic value of HLA-A2 status in advanced non-small cell lung cancer patientsLaura Mezquita, Melinda Charrier, Laura Faivre, et al.
European Respiratory Review : an Official Journal of the European Respiratory Society|March 2, 2016
KRAS oncogene in lung cancer: focus on molecularly driven clinical trialsEmmanuelle Kempf, Benoît Rousseau, Benjamin Besse, et al.
Bulletin Du Cancer|November 6, 2007
[Targeting epidermal growth factor receptor in non-small cell lung cancer: current advances and perspectives]Antoine Italiano, Benjamin Besse, David Planchard, et al.
Cancer Discovery|November 2, 2021
New Immunotherapy Combinations Enter the Battlefield of Malignant MesotheliomaMihaela Aldea, Jose Carlos Benitez, Nathalie Chaput, et al.
JCI Insight|May 5, 2022
Targeting genome integrity dysfunctions impedes metastatic potency in non-small cell lung cancer circulating tumor cell-derived explantsTala Tayoun, Vincent Faugeroux, Marianne Oulhen, et al.
Bulletin Du Cancer|June 14, 2020
[Immunotherapy of metastatic non-small cell lung cancer from first line to resistance and its management]Clémence Basse, Aurelie Swalduz, Matteo Giaj Levra, et al.
Therapeutic Advances in Medical Oncology|August 4, 2022
Current challenges of unresectable stage III NSCLC: are we ready to break the glass ceiling of the PACIFIC trial?Jordi Remon, Antonin Levy, Pawan Singh, et al.
Pageof 53